AbbVie vs Hyundai: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Hyundai was founded in 1967 by Chung Ju-yung and is led by Jose Munoz.
Company facts
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
Hyundai
Chung Ju-yung
Chung Ju-yung was a South Korean industrialist and the founder of the Hyundai group. He left the poor farming village where he grew up and in 1947 started a small civil engineering company.
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
Hyundai
- Chung Eui-sun2019–present
Executive Chair, Hyundai Motor Group (former co-CEO of Hyundai Motor)
He successfully elevated Hyundai and Kia from budget alternatives into highly desirable, premium-leaning brands, capturing significant global EV market share.
Source - Jaehoon Chang2021–2024
President and Chief Executive Officer
As co-CEO, he drove record-breaking operating profits in 2023 by prioritizing high-margin SUVs and luxury Genesis models amid global supply chain shortages.
Source - Jose Munoz2025–present
President and Chief Executive Officer
Munoz ran Hyundai's North American business and served as global COO before becoming CEO. Since 2025 he has led the response to U.S. tariffs, the $26 billion U.S. investment plan through 2028, the hybrid expansion and the 2030 target of 5.55 million sales.
Source
Timeline: AbbVie and Hyundai side by side
1967Hyundai
Hyundai Motor Company Founded
Chung Ju-yung established Hyundai Motor Company, creating the automotive arm that would become the flagship of South Korea's car industry.
1975Hyundai
Hyundai Pony
The Hyundai Pony became Korea's first mass-produced passenger car and gave Hyundai a domestic platform for exports and engineering learning.
1986Hyundai
U.S. Market Entry
Hyundai entered the U.S. market with the Excel, rapidly building awareness as a value-oriented global automaker.
1998Hyundai
Kia Stake Acquired
Hyundai acquired a controlling stake in Kia during the Asian financial crisis, creating the basis for Hyundai Motor Group's modern platform scale.
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2015Hyundai
Genesis Luxury Brand
Hyundai launched Genesis as a standalone luxury brand, supporting premiumization and higher-margin global growth.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2020Hyundai
E-GMP EV Platform
Hyundai introduced its dedicated E-GMP electric-vehicle platform, giving models such as Ioniq 5 and Ioniq 6 fast-charging and packaging advantages.
2021Hyundai
Boston Dynamics Acquisition
Hyundai Motor Group acquired a controlling stake in Boston Dynamics, adding robotics to its long-term mobility and automation strategy.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025Hyundai
Jose Munoz Becomes CEO
Jose Munoz, previously Hyundai's global COO and head of its North American business, became President and CEO effective January 1, 2025, succeeding Jaehoon Chang. He is the first non-Korean to lead the company.
2025Hyundai
Record Revenue, Tariff-Hit Profit
Hyundai reported FY2025 revenue of ~$132 billion (KRW 186.25 trillion), up 6.3%, while operating profit fell 19.5% to ~$8.14 billion (KRW 11.47 trillion) and net profit fell 21.7% to ~$7.36 billion (KRW 10.36 trillion), largely due to U.S. tariffs.
2025Hyundai
Georgia Battery Plant Raid
In September 2025, U.S. immigration agents detained hundreds of workers, many of them Korean, at the Hyundai-LG Energy Solution battery plant under construction in Georgia, delaying its opening by months.
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
2026Hyundai
Full Ownership of Boston Dynamics
In July 2026 Hyundai Motor Group moved to buy SoftBank's remaining stake in Boston Dynamics, a deal reported at about $325 million, making the robotics company wholly owned.
2026Hyundai
2026 CEO Investor Day
At its August 2026 CEO Investor Day, Hyundai reaffirmed a 2030 target of 5.55 million global sales and detailed its $26 billion U.S. investment plan through 2028.
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
Questions about AbbVie vs Hyundai
Who is the CEO of AbbVie Inc. and Hyundai Motor Company?
AbbVie Inc. is led by Robert A. Michael and Hyundai Motor Company is led by Jose Munoz. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs Hyundai Motor Company?
Hyundai Motor Company was founded in 1967 — 46 years before AbbVie Inc., which was founded in 2013. Hyundai Motor Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to Hyundai Motor Company?
AbbVie Inc. employs approximately 57,000 people, while Hyundai Motor Company employs approximately 123,000. Hyundai Motor Company has the larger workforce at 123,000 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and Hyundai Motor Company headquartered?
AbbVie Inc. is headquartered in United States and Hyundai Motor Company is headquartered in South Korea. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AbbVie Inc. and Hyundai Motor Company?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Hyundai Motor Company was founded by Chung Ju-yung.
Which company has a longer operating history — AbbVie Inc. or Hyundai Motor Company?
Hyundai Motor Company has been operating for approximately 59 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Hyundai overview